Leading Edge Genomic Services & Solutions

NovoPM™ Blood Tumor Mutation Burden

Service Overview
Novogene Data
Contact Us

Blood tumor mutation burden (bTMB) represents the total number of mutations per coding area of a tumor genome calculated through the genomic sequencing of circulating tumor DNA (ctDNA), an alternative source of diagnostic material for patients with inadequate tissue samples. The value of bTMB has been found to correlate with the efficacy of anti-PD-L1/PD-1 immunotherapies in some tumor types.

NovoPM-bTMB Algorithm

  • bTMB is calculated based on the coding DNA sequence (CDS) regions included in the NovoPM panel (approximately 1.5Mb).
  • Somatic mutations are identified with VarScan2.
  • The following mutations are excluded from the calculation of bTMB:
    • Germline mutations
    • Low frequency mutations (threshold=0.8%)
    • Known driver mutations (EGFR, MET, BRAF, PIK3CA, NF1, KRAS, and the NOTCH family genes)
    • Synonymous mutations
    • Repeat regions

NovoPM-bTMB Algorithm Validation

To analytically validate our NovoPM-bTMB algorithm, we sequenced 48 paired FFPE tumor tissue samples and ctDNA samples with NovoPM (1000X for tissue samples and 2000X for ctDNA samples). TMB and bTMB were then calculated as described above. The results showed good linear correlation (Figure 1; R2=0.7039).

Figure 1. Correlation between bTMB and TMB paired FFPE tumor tissue samples and ctDNA samples. X axis is bTMB calculated from NovoPM 2000X sequencing and Y axis is TMB calculated from NovoPM 1000X sequencing.

For Research Use Only. The content provided herein may relate to products that have not been approved for clinical use by the regulatory authorities of where this document is circulated. The application of such products should thus be limited to research only. The content of this document is subject to change without notice. © 2018 Novogene Co., LTD. All rights reserved. All trademarks are the property of Novogene Co., LTD and its subsidiaries unless otherwise specified.